TY - JOUR
T1 - Chronic kidney disease
AU - Levey, Andrew S.
AU - Coresh, Josef
N1 - Funding Information:
ASL has received payment for editorial board membership from the National Kidney Foundation (NKF), and grant support from NKF and Amgen. JC declares that he has no conflicts of interest.
Copyright:
Copyright 2021 Elsevier B.V., All rights reserved.
PY - 2012
Y1 - 2012
N2 - Chronic kidney disease is a general term for heterogeneous disorders affecting kidney structure and function. The 2002 guidelines for definition and classification of this disease represented an important shift towards its recognition as a worldwide public health problem that should be managed in its early stages by general internists. Disease and management are classified according to stages of disease severity, which are assessed from glomerular filtration rate (GFR) and albuminuria, and clinical diagnosis (cause and pathology). Chronic kidney disease can be detected with routine laboratory tests, and some treatments can prevent development and slow disease progression, reduce complications of decreased GFR and risk of cardiovascular disease, and improve survival and quality of life. In this Seminar we discuss disease burden, recommendations for assessment and management, and future challenges. We emphasise clinical practice guidelines, clinical trials, and areas of uncertainty.
AB - Chronic kidney disease is a general term for heterogeneous disorders affecting kidney structure and function. The 2002 guidelines for definition and classification of this disease represented an important shift towards its recognition as a worldwide public health problem that should be managed in its early stages by general internists. Disease and management are classified according to stages of disease severity, which are assessed from glomerular filtration rate (GFR) and albuminuria, and clinical diagnosis (cause and pathology). Chronic kidney disease can be detected with routine laboratory tests, and some treatments can prevent development and slow disease progression, reduce complications of decreased GFR and risk of cardiovascular disease, and improve survival and quality of life. In this Seminar we discuss disease burden, recommendations for assessment and management, and future challenges. We emphasise clinical practice guidelines, clinical trials, and areas of uncertainty.
UR - http://www.scopus.com/inward/record.url?scp=84855854046&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84855854046&partnerID=8YFLogxK
U2 - 10.1016/S0140-6736(11)60178-5
DO - 10.1016/S0140-6736(11)60178-5
M3 - Review article
C2 - 21840587
AN - SCOPUS:84855854046
SN - 0140-6736
VL - 379
SP - 165
EP - 180
JO - The Lancet
JF - The Lancet
IS - 9811
ER -